FINWIRES · TerminalLIVE
FINWIRES

Volatus Aerospace Completes Initial Flight Testing of V-Cortex

By

Volatus Aerospace (FLT.TO) completed initial flight testing of its proprietary V-Cortex AI Flight Controller and Autonomy Operating System, it said Tuesday.

The company said the testing demonstrated "GNSS-denied navigation without reliance on external sensors, using onboard default sensors to maintain flight".

The company plans additional flight testing and capability demonstrations throughout 2026, said Volatus.

"Successfully navigating without GPS or external sensors is a major technical milestone that validates our approach to resilient autonomy," said Chief Executive Officer Glen Lynch. "It brings us one step closer to delivering a Canadian-developed solution for defence, public safety, and critical infrastructure operators."

The company's shares were last seen up CA$0.01, or 1.6%, to CA$0.63 on the Toronto Stock Exchange.

Price: $0.63, Change: $+0.01, Percent Change: +0.81%

What else is happening in Wire?

Wire

Inghams Group Says Mitsubishi UFJ Financial's Stake in Firm Falls

Inghams Group (ASX:ING) said Mitsubishi UFJ Financial Group's voting power in the firm fell to 6.19% from 7.2% as of Sept. 16, according to a Tuesday Australian bourse filing.The Japanese bank holds nearly 23 million ordinary shares of the firm as of Sept. 16.Inghams Group's shares fell past 1% in recent trading on Tuesday.

ASX:ING
Wire

AnaptysBio Swings to Q2 Profit as Revenue Rises; Shares Gain After Hours

AnaptysBio (ANAB) reported Q2 net income late Monday of $5.11 per diluted share, swinging from the loss of $1.30 a year earlier.Revenue in the three months ended June 30 rose to $27.5 million from $22.3 million a year earlier.The company's shares rose 4.5% in after-hours trading.

$ANAB
Wire

Moderna Provides Details on Data Presentations at Upcoming Conferences

Moderna (MRNA) said Monday that phase 3 data for intismeran autogene in resected stage IIB-IV melanoma will be presented at a Presidential Symposium during the ESMO Congress 2026 on Oct. 24.The company said three abstracts on the investigational individualized neoantigen therapy were accepted for presentation, including data from a phase 1 pancreatic cancer study and a phase 3 lung cancer study.The company will also present in the Bernstein Insights Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum on Sept. 23, according to its website.Price: $173.39, Change: $+19.35, Percent Change: +12.56%

$MRNA